FDA Approved: PROCYSBI — Original Application (Horizon Therapeutics USA, Inc.)

View source ↗

Summary

The FDA approved Horizon Therapeutics' PROCYSBI (cysteamine bitartrate) through the original NDA 213491 for the treatment of nephropathic cystinosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nephropathic Cystinosis

Drugs mentioned

• Procysbi (mercaptamine bitartrate)

Snippet

ORIG AP for PROCYSBI (CYSTEAMINE BITARTRATE)